These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 28389440)
1. Haematological cancers: improving outcomes. A summary of updated NICE service guidance in relation to Specialist Integrated Haematological Malignancy Diagnostic Services (SIHMDS). Snowden JA; O'Connell S; Hawkins J; Dalley C; Jack A; Mannari D; McNamara C; Scott M; Shenton G; Soilleux E; Macbeth F; J Clin Pathol; 2017 Jun; 70(6):461-468. PubMed ID: 28389440 [TBL] [Abstract][Full Text] [Related]
2. Implementation of the updated NICE haematological cancers (NG47) improving outcomes guidelines across Specialist Integrated Haematological Malignancy Diagnostic Services (SIHMDS) in England: a UK NEQAS LI survey. Cartwright A; Snowden JA; Whitehouse H; Scott S; Whitby L J Clin Pathol; 2023 Sep; 76(9):618-623. PubMed ID: 35508367 [TBL] [Abstract][Full Text] [Related]
3. Specialist integrated haematological malignancy diagnostic services: an Activity Based Cost (ABC) analysis of a networked laboratory service model. Dalley C; Basarir H; Wright JG; Fernando M; Pearson D; Ward SE; Thokula P; Krishnankutty A; Wilson G; Dalton A; Talley P; Barnett D; Hughes D; Porter NR; Reilly JT; Snowden JA J Clin Pathol; 2015 Apr; 68(4):292-300. PubMed ID: 25631214 [TBL] [Abstract][Full Text] [Related]
4. Haematological cancers: improving outcomes. A summary of updated NICE service guidance in relation to Specialist Integrated Haematological Malignancy Diagnostic Services (SIHMDS). Cuthbert RJG J Clin Pathol; 2017 Jun; 70(6):469. PubMed ID: 28389439 [No Abstract] [Full Text] [Related]
5. Haematological malignancies: the rationale for integrated haematopathology services, key elements of organization and wider contribution to patient care. Ireland R Histopathology; 2011 Jan; 58(1):145-54. PubMed ID: 21261689 [TBL] [Abstract][Full Text] [Related]
6. Organisation of neoplastic haematopathology services: a UK perspective. Jack A Pathology; 2005 Dec; 37(6):479-92. PubMed ID: 16373228 [TBL] [Abstract][Full Text] [Related]
7. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Smith A; Howell D; Patmore R; Jack A; Roman E Br J Cancer; 2011 Nov; 105(11):1684-92. PubMed ID: 22045184 [TBL] [Abstract][Full Text] [Related]
9. What determines referral of UK patients with haematological malignancies to palliative care services? An exploratory study using hospital records. Ansell P; Howell D; Garry A; Kite S; Munro J; Roman E; Howard M Palliat Med; 2007 Sep; 21(6):487-92. PubMed ID: 17846088 [TBL] [Abstract][Full Text] [Related]
10. How many patients with haematological malignancy need the facilities offered by a district general hospital? Low J; Smith A; George S; Roderick P; Davis C J Public Health Med; 2002 Sep; 24(3):196-9. PubMed ID: 12831089 [TBL] [Abstract][Full Text] [Related]
11. The development of integrated haematopathology laboratories: a new approach to the diagnosis of leukaemia and lymphoma. Richards SJ; Jack AS Clin Lab Haematol; 2003 Dec; 25(6):337-42. PubMed ID: 14641135 [TBL] [Abstract][Full Text] [Related]
12. Translating biomedical science into clinical practice: Molecular diagnostics and the determination of malignancy. Cox H; Webster A Health (London); 2013 Jul; 17(4):391-406. PubMed ID: 23074299 [TBL] [Abstract][Full Text] [Related]
13. Trends in time to cancer diagnosis around the period of changing national guidance on referral of symptomatic patients: A serial cross-sectional study using UK electronic healthcare records from 2006-17. Price S; Spencer A; Zhang X; Ball S; Lyratzopoulos G; Mujica-Mota R; Stapley S; Ukoumunne OC; Hamilton W Cancer Epidemiol; 2020 Dec; 69():101805. PubMed ID: 32919226 [TBL] [Abstract][Full Text] [Related]
14. Incidence of haematological malignancies, Eastern Cape Province; South Africa, 2004-2013. Oelofse D; Truter I Cancer Epidemiol; 2018 Apr; 53():166-171. PubMed ID: 29462765 [TBL] [Abstract][Full Text] [Related]
15. Facilities for the treatment of adults with haematological malignancies--'Levels of Care': BCSH Haemato-Oncology Task Force 2009. Matthey F; Parker A; Rule SA; Wimperis JZ; Ardeshna KM; Bird JM; Cullis J; Lyttelton MP; McMillan A; Jackson GH Hematology; 2010 Apr; 15(2):63-9. PubMed ID: 20423565 [No Abstract] [Full Text] [Related]
16. Review of the NICE guidelines for multiple myeloma. Pratt G; Morris TC Int J Lab Hematol; 2017 Feb; 39(1):3-13. PubMed ID: 27997752 [TBL] [Abstract][Full Text] [Related]
17. [New horizons in evidence-based haematological oncology: outcome and importance of the scientific activities of the Cochrane Haematologicial Malignancies Group (CHMG)]. Kober T; Enger A Z Arztl Fortbild Qualitatssich; 2006; 100(3):167-73. PubMed ID: 16768081 [TBL] [Abstract][Full Text] [Related]
19. Estimating the prevalence of hematological malignancies and precursor conditions using data from Haematological Malignancy Research Network (HMRN). Li J; Smith A; Crouch S; Oliver S; Roman E Cancer Causes Control; 2016 Aug; 27(8):1019-26. PubMed ID: 27351920 [TBL] [Abstract][Full Text] [Related]